Understand the source comparison
Best Peptides for Post-Illness Immune Recovery: Evidence Comparison
Thymosin Alpha-1 TLR2 activation → T-cell maturation Thymic output, CD4+/CD8+ proliferation 1.6mg SC twice weekly × 8–12 weeks Phase III RCT data Gold standard for T-cell restoration. Strongest evidence base BPC-157 Tight junction repair → reduced endotoxin tr
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin Alpha-1
- TLR2 activation → T-cell maturation
- Thymic output, CD4+/CD8+ proliferation
- 1.6mg SC twice weekly × 8–12 weeks
- Phase III RCT data
- Gold standard for T-cell restoration. Strongest evidence base
- BPC-157
- Tight junction repair → reduced endotoxin translocation
- Intestinal barrier, systemic inflammation
- 250–500mcg SC daily × 4–8 weeks
- Preclinical + observational
- Addresses gut-immune axis neglected by other protocols
- LL-37 (Cathelicidin)
- FPR2 modulation → cytokine regulation
- Neutrophil/macrophage function, pathogen clearance
- 1–2mg intranasal or SC 2–3× weekly
- Phase II trials ongoing
- Dual antimicrobial + anti-inflammatory. Unique mechanism
- Thymosin Beta-4
- Actin sequestration → cell migration
- Wound healing, tissue repair
- 5–10mg SC 2× weekly × 6 weeks
- Phase II cardiac data
- Secondary immune benefit through tissue restoration